In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF

Human Reproduction

Volumn 20, Issue 9, 2005, Pages 2426-2433

  Lainas, Trifon ^a   Zorzovilis, John ^a   Petsas, George ^a   Stavropoulou, Georgia ^a   Cazlaris, Haris ^b   Daskalaki, Vassiliki ^c   Lainas, George ^d   Alexopoulou, Efthymia ^d  

^a Iatriki Erevna IVF Unit   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Criteria for antagonist initiation; Flexible antagonist protocol; GnRH antagonist

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZATION; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; OVARY FOLLICLE; OVULATION INDUCTION; PREDICTION; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 24044475262     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/dei106     Document Type: Article

References (31)

1. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K and Devroey P on behalf of the European Cetrorelix Study Group (2000) Ovarian stimulation with hMG: Results of a prospective randomized phase III European study comparing the luteinizing hormonereleasing hormone (LHRH)-antagonist cetrorelix and the LHRH agonist buserellin. Hum Reprod 15,526-531.
2. Al-Inany H and Aboulghar M (2002) GnRH antagonist in assisted reproduction: A Cochrane review. Hum Reprod 17,874-885.
3. Al-Inany HG, Aboulghar M, Mansour R and Serour GI (2005) Optimizing GnRH antagonist administration: Meta-analysis of fixed vs flexible protocol. Reprod Biomed Online 10, in press.
4. Bachelot A, Pouly JL, Devecchi Quenard A and de Mouzon J (1998) 1997 FIVNAT general balance. Contracept Fertil Sex 26,463-465.
5. Bosch E, Valencia I, Escudero E, Crespo J, Simon C, Remohi J and Pellicer A (2003) Premature luteinization during gonadotropin releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 80,1444-1449.
6. Brannstrom M and Enskog A (2002) Leukocyte networks and ovulation. J Reprod Immunol 57,47-60.
7. Cahill DJ, Wardle PG, Harlow CR and Hull MGR (1998) Onset of the preovulatory luteinizing hormone surge: Diurnal timing and critical follicular prerequisites. Fertil Steril 70,56-59.
8. Copperman AB (2003) Antagonists in poor responder patients. Real-life clinical applications of GnRH antagonists: Individualization of fertility treatment. Fertil Steril 80 (Suppl 1),16-24.
9. Dor J, Seidman DS, Ben-Shlomo I, Levran D, Karasik A and Mashiach S (1992) The prognostic importance of the number of oocytes retrieved and estradiol levels in poor and normal responders in in-vitro fertilization (IVF) treatment. J Assist Reprod Genet 9,228-232.
10. Escudero E, Bosch E, Crespo J, Simón C, Remohi J and Pellicer A (2004) Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilizationembryo transfer patients. Fertil Steril 81,562-566.
11. European Middle East Orgalutran Study Group (2001) Comparable clinical outcomes using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16,644-651.
12. European Orgalutran Study Group, Borm G and Mannaerts B (2000) Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial. Hum Reprod 15,1490-1498.
13. Felberbaum R and Diedrich K (2003) Gonadotropin-releasing hormone antagonists: Will they replace the agonists? Reprod Biomed Online 6, 43-53.
14. Ferin MJ (1996) The menstrual cycle: An integrative view. In Adashi EY, Rock JA, and Rosenwaks Z (eds) Reproductive Endocrinology, Surgery, and Technology, Vol. 1. Lippincott-Raven, New York, pp. 104-121.
15. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, Shapiro DB and Gordon K; the North American Ganirelix Study Group (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75,38-45.
16. Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM and Bouchard P (1991) Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist. Nal-Glu, in controlled ovarian hyperstimulation. Fertil Steril 56,923-927.
17. Kolibianakis E, Bourgain C, Albano C, Osmanagaoglou K, Smitz J, Van Steirteghem AC and Devroey P (2002) Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 78,1025-1029.
18. Kolibianakis E, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2003a) Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 79,873-880.
19. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2003b) Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: Effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 88,5632-5637.
20. Kolibianakis EM, Tarlatzis BC and Devroey P (2005) GnRH antagonists in IVF. Reprod Biomed Online 10, in press.
21. Lainas T, Petsas G, Stavropoulou G, Alexopoulou E, Iliadis G and Minaretzis D (2002) Administration of methylprednisolone to prevent ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril 78,529-533.
22. Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM and Diedrich K (2002) Tailoring the GnRH antagonist cetrorelix acetate individual patients' needs in ovarian stimulation for IVF: Results of a prospective randomized study. Hum Reprod 17,2842-2845.
23. Mochtar MH on behalf of The Dutch Ganirelix Study Group and (2004) The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. Hum Reprod 8,1713-1718.
24. Nelson LR, Fujimoto VY, Jaffe RB and Monroe SE (1995) Suppression of follicular phase pituitary gonadal function by a potent new gonadotropinreleasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril 63,963-969.
25. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P and Frydman R (2000) Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73,314-320.
26. Rabinovici J, Rothman P, Monroe SE, Nerenberg C and Jaffe RB (1992) Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties: Studies in menopausal women. J Clin Endocrinol Metab 75,1220-1225.
27. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81,19-25.
28. Schenker J and Weinstein D (1978) Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 30,255-268.
29. Shapiro DB (2003) GnRH antagonists in normal-responder patientsl. Reallife clinical applications of GnRH antagonists: Individualization of fertility treatment. Fertil Steril 80 (Suppl 1),8-15.
30. Surrey ES and Schoolcraft WB (2000) Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 73,667-676.
31. Tarlatzis BC, Zepiridis L, Grimbizis G and Bontis J (2003) Clinical management of low ovarian response to stimulation for IVF: A systematic review. Hum Reprod Update 9,61-76.